Edwards Lifesciences Corp (EW)vsNeuropace Inc (NPCE)
EW
Edwards Lifesciences Corp
$85.96
-1.70%
HEALTHCARE · Cap: $49.01B
NPCE
Neuropace Inc
$16.32
+2.77%
HEALTHCARE · Cap: $536.64M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 6233% more annual revenue ($6.30B vs $99.53M). EW leads profitability with a 17.4% profit margin vs -21.7%. EW earns a higher WallStSmart Score of 61/100 (C+).
EW
Buy61
out of 100
Grade: C+
NPCE
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.7%
Fair Value
$253.29
Current Price
$85.96
$167.33 discount
Margin of Safety
-24.3%
Fair Value
$11.71
Current Price
$16.32
$4.61 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
16.7% revenue growth
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 38.0x book value
ROE of -149.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bull Case : NPCE
NPCE has a balanced fundamental profile.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.
Bear Case : NPCE
The primary concerns for NPCE are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 4.87 is elevated, increasing financial risk.
Key Dynamics to Monitor
EW profiles as a growth stock while NPCE is a turnaround play — different risk/reward profiles.
NPCE carries more volatility with a beta of 1.88 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
NPCE generates stronger free cash flow (-6M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 21/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Neuropace Inc
HEALTHCARE · MEDICAL DEVICES · USA
NeuroPace, Inc. is a medical device company in the United States. The company is headquartered in Mountain View, California.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?